Literature DB >> 22568930

From tumor cell metabolism to tumor immune escape.

Martin Villalba1, Moeez G Rathore, Nuria Lopez-Royuela, Ewelina Krzywinska, Johan Garaude, Nerea Allende-Vega.   

Abstract

Tumorigenesis implies adaptation of tumor cells to an adverse environment. First, developing tumors must acquire nutrients to ensure their rapid growth. Second, they must escape the attack from the host immune system. Recent studies suggest that these phenomena could be related and that tumor cell metabolism may propel tumor immune escape. Tumor cell metabolism tends to avoid mitochondrial activity and oxidative phosphorylation (OXPHOS), and largely relies on glycolysis to produce energy. This specific metabolism helps tumor cells to avoid the immune attack from the host by blocking or avoiding the immune attack. By changing their metabolism, tumor cells produce or sequester a variety of amino acids, lipids and chemical compounds that directly alter immune function therefore promoting immune evasion. A second group of metabolism-related modification targets the major histocompatibility complex-I (MHC-I) and related molecules. Tumor MHC-I presents tumor-associated antigens (TAAs) to cytotoxic T-cells (CTLs) and hence, sensitizes cancer cells to the cytolytic actions of the anti-tumor adaptive immune response. Blocking tumor mitochondrial activity decreases expression of MHC-I molecules at the tumor cell surface. And peroxynitrite (PNT), produced by tumor-infiltrating myeloid cells, chemically modifies MHC-I avoiding TAA expression in the plasma membrane. These evidences on the role of tumor cell metabolism on tumor immune escape open the possibility of combining drugs designed to control tumor cell metabolism with new procedures of anti-tumor immunotherapy. This article is part of a Directed Issue entitled: Bioenergetic dysfunction, adaptation and therapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22568930     DOI: 10.1016/j.biocel.2012.04.024

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  37 in total

Review 1.  Causes of genome instability: the effect of low dose chemical exposures in modern society.

Authors:  Sabine A S Langie; Gudrun Koppen; Daniel Desaulniers; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Amaya Azqueta; William H Bisson; Dustin G Brown; Gunnar Brunborg; Amelia K Charles; Tao Chen; Annamaria Colacci; Firouz Darroudi; Stefano Forte; Laetitia Gonzalez; Roslida A Hamid; Lisbeth E Knudsen; Luc Leyns; Adela Lopez de Cerain Salsamendi; Lorenzo Memeo; Chiara Mondello; Carmel Mothersill; Ann-Karin Olsen; Sofia Pavanello; Jayadev Raju; Emilio Rojas; Rabindra Roy; Elizabeth P Ryan; Patricia Ostrosky-Wegman; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Frederik J Van Schooten; Mahara Valverde; Jordan Woodrick; Luoping Zhang; Nik van Larebeke; Micheline Kirsch-Volders; Andrew R Collins
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

2.  MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells.

Authors:  Elena Catalán; Seyma Charni; Paula Jaime; Juan Ignacio Aguiló; José Antonio Enríquez; Javier Naval; Julián Pardo; Martín Villalba; Alberto Anel
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 3.  The Warburg effect: molecular aspects and therapeutic possibilities.

Authors:  Hanh Ngo; Stephanie M Tortorella; Katherine Ververis; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2015-04       Impact factor: 2.316

4.  Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells.

Authors:  Diego Sánchez-Martínez; Gemma Azaceta; Aura Muntasell; Nacho Aguiló; David Núñez; Eva M Gálvez; Javier Naval; Alberto Anel; Luis Palomera; Carlos Vilches; Isabel Marzo; Martín Villalba; Julián Pardo
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

5.  IFNα signaling through PKC-θ is essential for antitumor NK cell function.

Authors:  Natalia R Comet; Juan Ignacio Aguiló; Moeez G Rathoré; Elena Catalán; Johan Garaude; Gilles Uzé; Javier Naval; Julián Pardo; Martín Villalba; Alberto Anel
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

Review 6.  Chemical metabolic inhibitors for the treatment of blood-borne cancers.

Authors:  Martin Villalba; Nuria Lopez-Royuela; Ewelina Krzywinska; Moeez G Rathore; Robert A Hipskind; Houda Haouas; Nerea Allende-Vega
Journal:  Anticancer Agents Med Chem       Date:  2014-02       Impact factor: 2.505

7.  24-Hydroxycholesterol participates in pancreatic neuroendocrine tumor development.

Authors:  Matias Soncini; Gianfranca Corna; Marta Moresco; Nadia Coltella; Umberto Restuccia; Daniela Maggioni; Laura Raccosta; Chin-Yo Lin; Francesca Invernizzi; Roberto Crocchiolo; Claudio Doglioni; Catia Traversari; Angela Bachi; Rosa Bernardi; Claudio Bordignon; Jan-Åke Gustafsson; Vincenzo Russo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

8.  NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.

Authors:  Dang-Nghiem Vo; Catherine Alexia; Nerea Allende-Vega; Franck Morschhauser; Roch Houot; Cedric Menard; Karin Tarte; Guillaume Cartron; Martin Villalba
Journal:  Oncoimmunology       Date:  2017-12-20       Impact factor: 8.110

9.  Oxysterols recruit tumor-supporting neutrophils within the tumor microenvironment: The many facets of tumor-derived oxysterols.

Authors:  Laura Raccosta; Raffaella Fontana; Catia Traversari; Vincenzo Russo
Journal:  Oncoimmunology       Date:  2013-10-10       Impact factor: 8.110

Review 10.  Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy.

Authors:  Huixian Zhang; Wencheng Zhao; Xingya Li; Yayi He
Journal:  Onco Targets Ther       Date:  2021-06-21       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.